Navigation Links
Jennerex and Transgene Announce Presentation of Phase 1 Data Demonstrating that JX-594 Administration Targets Tumor Vasculature
Date:4/5/2011

lable on the internet at www.transgene.fr

About Green Cross Corp.:

Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Cautionary note for Transgene regarding forward-looking statements

This press release contains forward-looking statements referring to the joint clinical testing and development and commercial potential of JX-594. Clinical testing and successful product development and commercialization depend on a variety of factors, including the timing and success of future patient enrolment, the risk of unanticipated adverse patient reactions, regulatory approval and the level of demand for the product by the medical community. Results from future studies with more data may show less favorable outcomes than prior studies, and there is no certainty that product candidates will ever demonstrate adequate therapeutic efficacy or achieve regulatory approval or commercial success. In addition, forward-looking statements regarding product development, testing and marketing costs are by the nature subject to uncertainties as a result of unforeseen difficulties and expenses which may arise, and future product development costs may exceed current expectations.  For further information on the risks and uncertainties involved in the testing and development of Transgene's product candidates, see Transgene's Document de Reference on file with the French Autorite des marches financiers on its w
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
2. Jennerex Names Ursula Fritsch, PharmD, as Vice President, Regulatory Affairs
3. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
4. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
5. Jennerex Appoints Lara Longpre to Chief Operating Officer
6. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
7. Jennerex Announces Presentations at Upcoming Conferences
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Developed by AstraZeneca plc, quetiapine (under ... drug for the treatment of schizophrenia. Approved by ... listed in the Catalogue of Drugs for the ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... SAN MARINO, Calif. , July 6 ... of targeted genetic medicine, received a notice of allowance ... leading tumor-targeted gene delivery platform. The issuance of this ... follows on the heels of two major patent issuances ...
... N.J. , July 6 Nephros, Inc. (OTC Bulletin ... for therapeutic applications, infection control, and water purification, today reported that ... a standard component of its MRO portable reverse osmosis water treatment ... , ...
Cached Medicine Technology:Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 2Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 2Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 3Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 4Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems 5
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced ... Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably ... LLC (VHS) in the United States District Court for the Southern District of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately ... the Zoo to celebrate children helping children, a thank you to the many ... Ohio have contributed to the United Methodist initiative to end malaria deaths. , ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is ... with their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known ... stroke. They believe that together, a difference can be made. Walkers can participate in ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 , ... ... in Western Michigan, joined as sponsor of the “Music With A Mission” benefit concert ... purpose behind the event was to raise money to support music education programs in ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... Feb. 21 AK Steel (NYSE:,AKS) said today that ... agreement between AK Steel and a group of retirees ... from the company,s,initiatives in 2006 to reduce its health ... settlement agreement, which established a Voluntary Employees,Beneficiary Association (VEBA) ...
... Feb. 21 The needs of,pregnant women, babies and toddlers ... Healthy Start of Southwest Florida has received a $6,000,grant from ... how we,can best help the 18,000 clients we serve each ... in the last five,years. The population has increased and the ...
... new electron microscope recently installed in Cornell,s Duffield Hall ... images that uniquely identify individual atoms in a crystal ... And in living color. , "The current generation of ... and white cameras where different atoms appear as different ...
... whose discoveries have led to fundamental advances in the ... two prestigious international prizes offered by the Kirk A. ... for Cancer Research (AACR). , The Kirk A. ... Landon-AACR Prize for Translational Cancer Research are among the ...
... Sons, Inc. (NYSE: JWa), (NYSE: JWb), today announced that it ... its worldwide operations that were formerly part of Blackwell Publishing, ... addition to offsetting the carbon footprint of 10 offices around ... that result from the global product shipments from this part ...
... of adverse side effects , , THURSDAY, Feb. ... one nonsteroidal anti-inflammatory drug (NSAID) may have poorer health-related ... which are available in both prescription and over-the-counter (OTC) ... drugs are widely available, and patients may take both ...
Cached Medicine News:Health News:U.S. Court Approves AK Steel's VEBA Health Care Settlement With Middletown Works Retirees 2Health News:Healthy Start of Southwest Florida Receives Grant From March of Dimes to Assess Needs of Pregnant Women and Babies 2Health News:By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis 2Health News:By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis 3Health News:AACR's Seventh Annual Landon Awards 2Health News:AACR's Seventh Annual Landon Awards 3Health News:AACR's Seventh Annual Landon Awards 4Health News:AACR's Seventh Annual Landon Awards 5Health News:Taking Multiple Pain Relievers May Cause Complications 2
... anyone using the Farnsworth D15, L'Anthony desaturated test ... patients cannot avoid touching the color disks with ... Further, the disks are very easy to loose.,We ... in order to solve these problems. We have ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: